A detailed history of Vestal Point Capital, LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 3,250,000 shares of ATXS stock, worth $38.4 Million. This represents 2.21% of its overall portfolio holdings.

Number of Shares
3,250,000
Previous 1,100,000 195.45%
Holding current value
$38.4 Million
Previous $15.5 Billion 91.02%
% of portfolio
2.21%
Previous 1.28%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.83 - $13.51 $19 Million - $29 Million
2,150,000 Added 195.45%
3,250,000 $29.6 Billion
Q1 2024

May 13, 2024

BUY
$6.99 - $16.69 $7.69 Million - $18.4 Million
1,100,000 New
1,100,000 $15.5 Billion

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $179M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Vestal Point Capital, LP Portfolio

Follow Vestal Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestal Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Vestal Point Capital, LP with notifications on news.